 RADNOR, Pa., May 26, 2021 PRNewswire -- Today, NRx Pharmaceuticals, Inc., Nasdaq:NRXP NRx through its Georgia subsidiary, announced that it has signed a master services agreement with Cromos Pharma, LLC, headquartered in Longview, Washington, to conduct phase 3 clinical trials of COVID-19 related drugs and vaccines in Central Europe and the Caucasus Region. 